Xinxin Ding, PhD

Department Head, Pharmacology and Toxicology
Professor, Pharmacology & Toxicology
Professor, BIO5 Institute
Member, University of Arizona Cancer Center
Member, Southwest Environmental Health Sciences Center

Xinxin Ding, PhD, department head, Pharmacology and Toxicology, College of Pharmacy—studies enzyme function, regulation and genetics as applied to translational research for drug safety and efficacy and genetic and environmental risks for chemical toxicity.

Author of nearly 200 peer-reviewed papers, book chapters and articles, he serves as associate editor for “Drug Metabolism and Disposition” and “Acta Pharmaceutica Sinica B.” Grants from the National Cancer Institute and National Institute of Environmental Health Sciences of the National Institutes of Health fund his work, in part. Former chair of the NIH XNDA study section (2016-2018), he chaired (2018-19) the Drug Metabolism and Disposition Division of the American Society for Pharmacology and Experimental Therapeutics.

View UA Profile

Education & Post Graduate Training: 

PhD, Biological Chemistry, Medical School, University of Michigan, 1988
BS, Biology (Medical Physiology), Nanjing University (Nanjing, China), 1982

Areas of Research: 

Drug metabolism/disposition
Enzyme function/regulation
Drug safety/efficacy
Genetic/environmental risks for chemical toxicity

Types of Research: 
Laboratory-based Research
Professional Organizations: 

American Society for Biochemistry and Molecular Biology, member (1988-Present)
International Society for the Study of Xenobiotics, Member (1993-Present)
Society of Toxicology, Member (1995-Present)
American Society for Pharmacology and Experimental Therapeutics, Member (1997-Present); Chair of Drug Metabolism and Disposition Division (2018-2019)
American Association for Cancer Research, member (2004-Present)

Select Publications

2017

Li, L., S. Carratt, M. Hartog, N. Kovalchik, K. Jia, Y. Wang, Q-Y. Zhang, P. Edwards, L. Van Winkle, and X. Ding, "Human CYP2A13 and CYP2F1 Mediate Naphthalene Toxicity in the Lung and Nasal Mucosa of CYP2A13/2F1-Humanized Mice.", Environ Health Perspect, vol. 125, issue 6, pp. 067004, 2017 06 08. PMCID: PMC5743450  PMID: 28599267

2010

Conroy, J. L., C. Fang, J. Gu, S. O. Zeitlin, W. Yang, J. Yang, M. A. VanAlstine, J. W. Nalwalk, P. J. Albrecht, J. E. Mazurkiewicz, et al., "Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling.", Nat Neurosci, vol. 13, issue 3, pp. 284-6, 2010 Mar. PMCID: PMC2828325  PMID: 20139973

2007

Weng, Y., C. Fang, R. J. Turesky, M. Behr, L. S. Kaminsky, and X. Ding, "Determination of the role of target tissue metabolism in lung carcinogenesis using conditional cytochrome P450 reductase-null mice.", Cancer Res, vol. 67, issue 16, pp. 7825-32, 2007 Aug 15. PMID: 17699788

2003

Gu, J., Y. Weng, Q-Y. Zhang, H. Cui, M. Behr, L. Wu, W. Yang, L. Zhang, and X. Ding, "Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase.", J Biol Chem, vol. 278, issue 28, pp. 25895-901, 2003 Jul 11. PMID: 12697746

2000

Su, T., Z. Bao, Q. Y. Zhang, T. J. Smith, J. Y. Hong, and X. Ding, "Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.", Cancer Res, vol. 60, issue 18, pp. 5074-9, 2000 Sep 15. PMID: 11016631